Skip to main content

PNC-27: Cancer Research, Human Evidence Gaps and Safety

By the Peptide Dossier Editorial TeamUpdated How we source

Published

Direct answer: PNC-27 is an experimental, p53-derived peptide studied for its ability to damage selected cancer-cell membranes. Published work includes cultured cancer cells, cells obtained from patients and mouse models. Those are not clinical trials treating people. Our November 22, 2026 search identified no registered PNC-27/PNC27 study in ClinicalTrials.gov and no prospective human treatment trial in the matched literature. A separate 2017 conference case abstract reports human exposure followed by severe bleeding; causation was unresolved. PNC-27 is not an established cancer treatment. [1–7,13]

Key findings

  • A human safety observation exists. A 2017 conference case report is separate from the preclinical efficacy studies and does not establish causation. [13]
  • Human cells are not human treatment evidence. Ovarian tumor samples and leukemia blasts were exposed to PNC-27 outside the patients' bodies. [3,4]
  • There is genuine animal research. An AML study included mouse leukemia and human-cell xenograft models. Calling the entire evidence base “cell culture only” would miss those experiments. [4]
  • PNC-28 is a different peptide. Closely related sequences, conjugated nanoparticles and combination experiments must retain their own identities. [1,8,9]
  • A proposed mechanism is not a demonstrated patient benefit. Membrane pores, mitochondrial changes and reduced cell viability do not measure cancer remission, quality of life or survival in people. [2,5,6]
  • Product quality is a separate risk. FDA documented bacterial contamination in a PNC-27 product promoted for cancer. That historical finding neither measures every current product nor validates uncontaminated products as effective. [10]

This guide provides an evidence map and a way to read the claims. For broader context, see our research-peptides guide and peptide safety reference.

What PNC-27 is—and what the name does not mean

PNC-27, also written PNC27, is a synthetic 32-amino-acid peptide. It joins a segment corresponding to residues 12–26 of p53 to a membrane-associated leader sequence. The p53 segment provides a binding region for HDM2, also written HDM-2 or MDM2 in this literature. The leader is described as a membrane residency or penetrating peptide. [1,2]

The number in the development name should not be used to infer peptide length, dose or a treatment cycle. Nor does “p53-derived” mean that the product replaces the whole p53 protein or repairs a patient's tumor-suppressor gene. The identity is a starting point for matching an experiment to the correct material.

The same caution applies to “HDM2 targeting.” A target name can appear in several research strategies. A compound intended to disrupt an intracellular p53–HDM2 interaction is not automatically equivalent to a membrane-active peptide. Sharing a protein target does not transfer clinical results from one drug program to another.

Name or preparationIdentity in the cited workEvidence boundary
PNC-27 / PNC2732-residue p53-derived peptide with a linked leader sequence [1,2]Main subject of this guide; experimental preparation must still be matched
PNC-28Shorter related peptide containing a different p53 segment [1]Its individual experiments are not automatically PNC-27 results
PNC-29 and PNC-26Control peptides in particular experiments [2,4]Controls help test specificity; they are not alternative clinical products
PNC-27 plus paclitaxelCombination tested in ovarian cancer experiments [8]A combination result cannot establish the peptide's standalone effect or a human regimen
PNC-27–targeted PEI-SPIONsPeptide-linked nanoparticle carrier studied in vitro [9]A diagnostic-delivery formulation, not evidence for an ordinary PNC-27 vial

This identity map prevents a common error: collecting every favorable paper with a similar name and treating the collection as one clinically tested product. Formulation, linked cargo, comparator and experimental setting all matter.

Proposed mechanism: membrane damage rather than a clinical response

The central hypothesis is that PNC-27 binds membrane-associated HDM2 in susceptible cancer cells, contributing to pores that disrupt the membrane. The 2010 PNAS paper combined structural comparisons, binding experiments and cell experiments. Importantly, normally resistant breast epithelial cells became susceptible after researchers engineered membrane-localized HDM2 expression. That supports a role for the membrane target under those experimental conditions. [1]

A 2022 original study added modeling and immuno-electron microscopy. The investigators observed PNC-27 and HDM2 labeling associated with pore structures in treated pancreatic cancer cells, alongside controls using untransformed cells. This is mechanistic evidence in a laboratory model, not direct observation of a tumor responding inside a treated person. [2]

Later pancreatic-cell work reported antibody-blocking experiments and changes in mitochondrial staining and morphology. An antibody against the relevant HDM2 region blocked the cell-killing effect; treated mitochondria lost functional dye retention, and immuno-electron microscopy localized peptide-associated labeling to mitochondrial membranes. These findings extend the proposed mechanism without establishing a safe human exposure or a clinical response rate. [5]

Selectivity also varies across experimental models. A separate 2010 study using PNC27 as a model reported tumor-cell IC50 values only two to three times lower than normal-cell values. Experiments replacing the penetrating sequence implicated that sequence and chondroitin-sulfate-associated entry in preferential cytotoxicity. Its original abstract supports a model-dependent effect, not an absolute cancer-versus-normal divide. These findings are another reason to treat the membrane-HDM2 account as a research hypothesis whose clinical relevance remains to be established. [14]

Terms such as necrosis, membranolysis and pore formation describe cellular events. They should not be translated into “selectively eliminates every tumor” or “has no side effects.” The biologically important question is whether an intervention can produce a useful effect at a tolerable exposure in the whole organism. The cited human-cell experiments do not answer that clinical question.

Evidence map: separate cells, animals and people

The table deliberately labels the unit receiving the intervention. A paper can contain material from human patients while remaining an ex vivo experiment. Similarly, “human AML model” can mean human cells growing in mice.

Original studyDesign and modelReported resultMain limitation
Sarafraz-Yazdi et al., 2010 [1]Structural, binding and cultured-cell experiments, including engineered membrane HDM2Findings supported membrane-associated HDM2 as a determinant of susceptibilityMechanistic experiments; no patients treated
Sarafraz-Yazdi et al., 2015 [3]Cultures from two freshly isolated ovarian cancers plus established linesDose-dependent cytotoxicity; control PNC-29 lacked the observed effectTwo primary tumor sources; ex vivo response is not a patient response
Wang et al., online 2019 / issue 2020 [4]Human AML samples, normal donor cells, mouse AML and human AML xenograftsLaboratory activity and longer survival in selected treated mouse cohortsMultiple small preclinical cohorts; no human dosing or clinical outcome
Sarafraz-Yazdi et al., 2022 [2]Modeling, microscopy and cultured cancer-cell controlsPore structures associated with PNC-27/HDM2 labelingSupports a proposed mechanism, not clinical selectivity
Krzesaj et al., 2024 [5]Pancreatic cancer cells; antibody blockade, organelle dyes and microscopyFindings supported HDM2 interaction and mitochondrial disruptionCell-based mechanistic report; no human safety assessment
Krzesaj et al., 2025 [6]SiHa cervical cancer cells versus an untransformed cervical cell lineCancer-cell IC50 reported as 12.4 micromolar; differential viabilityOne cancer/control cell-line comparison is not a cervical cancer trial
Separate 2010 penetratin study [14]Cultured tumor and normal cells; altered leader sequencesPNC27 tumor-cell IC50 two to three times lowerRelative, model-dependent selectivity; no human safety conclusion
Aguon et al., 2017 [13]Human conference case abstractBleeding after exposure; later deathUncontrolled observation; causation unresolved

Human-derived ovarian cells: why “ex vivo” matters

The 2015 ovarian paper established cultures from two surgically obtained cancers, one mucinous and one high-grade papillary serous. PNC-27 reduced growth and produced cytotoxicity in those cultures; the paper also examined established, chemotherapy-resistant ovarian cancer lines. The accessible original abstract supports those findings. It does not describe administering PNC-27 to the two patients. [3]

The distinction changes the denominator. Two tumor sources are not two treated patients with measured remission or survival. A response in isolated cells also does not establish that a substance reaches all relevant tumor sites, maintains an effective concentration or avoids harmful exposure elsewhere in a person.

Leukemia experiments: meaningful animal data with limited translation

The AML paper tested primary membrane-HDM2-positive blasts from 12 patients and normal CD34-positive cells from nine donors in its cytotoxicity comparison. Those samples were exposed outside the body. In a separate mouse leukemia survival experiment, median survival was 54 days with PNC-27, 41 with control peptide PNC-29 and 42 with vehicle; group sizes were nine, ten and ten mice respectively. [4]

The authors also studied human AML xenografts and transplantation-based measures of leukemia-initiating activity. These broaden the preclinical evidence, but the recipients were mice. Their survival curves are not estimates of additional life expectancy for people with AML. The paper's online publication in July 2019 and January 2020 journal issue are two dates for the same report, not independent replications. [4]

Recent cervical-cell findings: a concentration is not a prescription

The 2025 report compared HTB-35/SiHa cancer cells with PCS-480 untransformed cervical cells. It reported an IC50 of 12.4 micromolar in the cancer-cell experiment and membrane-HDM2 findings. We checked the original indexed abstract; the publisher's full text was not accessible through our research tools. [6]

An IC50 is an assay-specific concentration associated with half-maximal inhibition in that experiment. It is not a dose for a person, a probability of remission or a guarantee that the concentration is attainable safely. Converting it to an injection schedule would require evidence this experiment does not provide.

Combinations and delivery systems answer different questions

A 2017 original ovarian-cancer report examined PNC-27 after paclitaxel exposure, including ID8 cells and a mouse model. It reported synergistic cytotoxicity in vitro and reduced tumor growth when PNC-27 was added to paclitaxel in the animal experiment. This is combination evidence, not a validated patient treatment schedule. [8]

Likewise, a 2022 study attached PNC-27 to a polyethyleneimine/superparamagnetic iron oxide nanoparticle system and evaluated targeting in cell models. Uptake and targeting results for that constructed carrier do not demonstrate that free peptide has the same distribution, imaging performance or toxicity. [9]

For a reader comparing claims, the practical rule is to keep the experimental object intact. A peptide used as a carrier ligand, a free peptide applied to cells and a peptide combined with chemotherapy are three different interventions. Combining their most attractive outcomes produces a fictional product that no single study actually tested.

Human trials and current research status

On November 22, 2026, the official ClinicalTrials.gov API query for PNC-27 or PNC27 returned zero studies. We also refreshed an exact-name PubMed search and screened the returned records for the compound and study setting. No prospective human treatment trial was identified in that matched set. A separate conference case abstract describes actual human exposure, as discussed below; it was outside that PubMed result set. Registry and index searches are dated, bounded checks, not proof that no other report exists. [7,13]

This boundary is particularly important because indexing terms can mislead. A “Humans” tag may reflect the origin of a cell line or tumor sample. It does not, by itself, mean that volunteers received the peptide. Read the methods for who or what received the intervention, how outcomes were measured and whether adverse events were collected from actual participants.

The current evidence therefore cannot provide a human response rate, tolerated dose, drug-interaction profile, treatment duration or estimate of benefit relative to standard cancer care. FDA's clinical-research framework explains why safety and efficacy require studies in people after preclinical work. A promising mechanism is a reason to investigate, rather than a substitute for those studies. [11]

Published human exposure: a safety observation, not a trial

Aguon and colleagues' October 2017 conference case abstract describes massive gastrointestinal bleeding beginning two days after PNC-27 infusion in a person with advanced metastatic cervical cancer. The patient later died after transition to comfort care. The authors explicitly leave causation unresolved. [13]

This uncontrolled report cannot determine a side-effect rate, establish efficacy or prove that PNC-27 caused the bleeding or death. It does document reported human exposure and a serious subsequent event, so “no human reports” would be misleading. It must remain separate from prospective clinical-trial evidence.

Safety and regulatory context

There are two separate questions: the risks of the experimental molecule and the quality of a marketed preparation. Neither is settled by a favorable cancer-cell image.

In the AML study, the investigators examined normal hematopoiesis in mice and found no significant differences in selected blood and stem-cell measures under their test conditions. That is useful preclinical safety information within the endpoints measured. It is not a complete assessment of every organ, repeated human exposure, immune reactions or interactions with anticancer medicines. [4]

FDA's cancer-product guidance records a different, product-specific problem: its laboratory found Variovorax paradoxus in a sample of PNC-27 marketed as a cancer treatment in January 2017. This is a historical contamination finding, not a survey estimating current contamination prevalence. It also means that a chemical-purity percentage alone cannot answer every question about a preparation. [10]

A May 2021 Department of Justice release documents enforcement involving unapproved PNC-27 products sold as cancer treatment and states that PNC-27 was not FDA approved for any disease. We retain that event date rather than presenting the announcement as a new action. Our current evidence review did not identify an approved PNC-27 prescribing label. [12]

Claim a reader may encounterWhat the evidence can establishWhat remains unestablished
“Kills human cancer cells”Activity against specified cells in a defined assayA treatment response in a person
“Spares normal cells”Selected control cells or measured animal endpoints were relatively sparedWhole-body human safety or absence of adverse effects
“Research grade” or a high purity percentageA claim requiring its own product and analytical documentationClinical efficacy, suitable manufacturing and comprehensive safety
“Targets HDM2”A proposed interaction supported by particular experimentsEquivalence to other HDM2 drugs or a clinically validated selection test
“Listed in PubMed”A bibliographic record existsRegulatory approval, independent replication or a clinical trial

For someone facing a cancer diagnosis, these distinctions have a direct implication: this literature does not justify replacing or delaying established oncology care with PNC-27. FDA specifically warns that unproven cancer products can cause indirect harm by delaying beneficial treatment. A discussion with the treating oncology team should include any experimental product being considered. [10]

Questions that help evaluate a PNC-27 claim

Has PNC-27 been shown to cure cancer in people?

The matched evidence reviewed here does not establish that claim. Cells dying in a dish and longer survival in selected mouse experiments are different endpoints from durable remission or survival in patients. Testimonials cannot supply the missing comparison, participant accounting or safety follow-up.

Is PNC-27 the same as PNC-28?

No. They are related peptides with different p53-derived segments. Check the actual intervention in the original study before assigning its result to either name. Similarly, a review discussing both compounds is not an additional experiment demonstrating both. [1]

Does membrane HDM2 identify patients who will benefit?

The laboratory findings support investigating that hypothesis. They do not establish a clinically validated companion diagnostic, threshold or treatment-selection pathway. Measuring a target and proving that a test predicts meaningful benefit are separate tasks.

Would a certificate of analysis resolve the uncertainty?

A report can address the analytes and sample it actually tested. It cannot establish human benefit or fill missing clinical safety data. Identity, content, impurities, microbiological quality and clinical performance require different evidence. Our certificate-of-analysis guide explains how to read the scope of a report.

What would strengthen the evidence?

Well-documented human studies would need to identify the preparation and manufacturing controls, measure exposure, prospectively collect adverse events and report clinically meaningful outcomes. Later comparative studies would need transparent participant accounting, appropriate controls and sufficient follow-up. Reporting negative findings and independent replication would also help distinguish a reproducible therapeutic effect from a promising experimental observation.

Editorial methods and references

Prepared by the Peptide Dossier Editorial Team with AI assistance under our editorial policy. Sources checked November 22, 2026. This is a targeted editorial synthesis, not a systematic review or clinician-reviewed recommendation. We read accessible original full reports and original indexed abstracts as identified below, and checked the official trial registry. We claim no personal treatment experience, validated human protocol or comprehensive worldwide absence of evidence. Laboratory findings, animal outcomes and human treatment evidence remain separate throughout.

  1. Sarafraz-Yazdi et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. PNAS. 2010;107:1918–1923. DOI 10.1073/pnas.0909364107; PMID 20080680. Original paper hosted by CDC.

  2. Sarafraz-Yazdi et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2…. Biomedicines. April 20, 2022;10:945. DOI 10.3390/biomedicines10050945; PMID 35625682. Original mechanistic study.

  3. Sarafraz-Yazdi et al. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer. Ann Clin Lab Sci. Fall 2015;45:650–658. Original abstract; full-text access unavailable.

  4. Wang et al. Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. Online July 23, 2019;2020;34:75–86. DOI 10.1038/s41375-019-0522-9; PMID 31337857. Full original report retrieved through NCBI's text service.

  5. Krzesaj et al. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes…. Ann Clin Lab Sci. March 2024;54:137–148. Original indexed abstract.

  6. Krzesaj et al. HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells. Ann Clin Lab Sci. May 2025;55:347–353. Original indexed abstract.

  7. ClinicalTrials.gov: exact-name search for PNC-27 or PNC27. Official API checked November 22, 2026; zero returned studies. Search scope and date retained above.

  8. Alagkiozidis et al. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer. Ann Clin Lab Sci. May 2017;47:271–281. Original indexed abstract; cell and mouse combination experiments.

  9. Rahmani et al. Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles as a double targeting agent for early cancer diagnosis: In vitro study. Iran J Basic Med Sci. October 2022;25:1234–1242. Original indexed abstract; carrier-specific findings.

  10. FDA: Questions and Answers on products claiming to treat cancer. Official source documents the January 2017 PNC-27 contamination finding and treatment-delay concerns; checked November 22, 2026.

  11. FDA: Step 3, Clinical Research. Official explanation of studies in people and phase-specific purposes; checked November 22, 2026.

  12. U.S. Department of Justice: Birmingham Man Sentenced for Making Unapproved Drug Products. May 26, 2021. Historical enforcement and approval-status statement; not a current global legal opinion.

  13. Aguon PM, Aasen T, Distler ES, Mallin E. Experimental PNC-27 Therapy and Massive GI Hemorrhage: A Complication or Coincidence?. Am J Gastroenterol. October 2017;112:S1035–S1036. Original conference case abstract; causal relationship unresolved.

  14. Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem. August 13, 2010;285:25666–25676. DOI 10.1074/jbc.M109.089417. Original indexed abstract; PNC27 and constructed comparator peptides distinguished.